Examining 3 major risk factors of AMD

Video

Joshua Mali, MD, discusses the three major risk factors for developing age-related macular degeneration (AMD).

Joshua Mali, MD, retina medical director, Macular Degeneration Association; vitreoretinal surgeon at The Eye Associates (Sarasota, FL); founder, CEO, Mali Enterprises, discusses the three major risk factors for developing age-related macular degeneration (AMD).

See more AMD Awareness content here, here, and here.

Recent Videos
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
Images of a chest X-ray and a CT scan show the chest and vascular system following a COVID-19 infection. Image credit: ©samunella – stock.adobe.com

EDI-OCT and CVI findings can shed light on choroidal vascular physiology following COVID-19 pneumonia

Lynda Charters
March 17th 2025
Article

Investigators measured the choroidal structures using enhanced depth imaging optical coherence tomography

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A person in scrubs holds their hand outstretched toward the camera. A digital overlay gives the impression that the doctor or clinician is offering information about the future of eye care and retinal health. Image credit: ©sdecoret – stock.adobe.com

Advanced therapies in neovascular AMD and DMO: Experts weigh in

Hattie Hayes
March 12th 2025
Article

A clinician panel illuminates current treatment paradigms and best practices for reducing treatment burden

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

Sun rays stretch over the horizon as a sun rises or sets against a blue sky. Image credit: ©Pavlo Vakhrushev – stock.adobe.com

Experts say revakinagene taroretcel-lwey approval may represent dawn of new treatments for neurodegenerative conditions

Sheryl Stevenson;Anat Loewenstein, MD, MHA;Rishi P. Singh, MD;Martin Friedlander, MD, PhD;Mohammad Rafieetary, OD, FAAO
March 10th 2025
Article

Clinicians react to the US approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals) for macular telangiectasia type 2

The Heidelberg Congress Center in Heidelberg, Germany. Image courtesy of Heidelberg Engineering.

Heidelberg Engineering announces two-day International SPECTRALIS Symposium

Hattie Hayes
March 7th 2025
Article

The event will include presentations on artificial intelligence, ocular imaging and surgical topics

© 2025 MJH Life Sciences

All rights reserved.